Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1995-3-10
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0003-987X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
131
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
228
|
pubmed:dateRevised |
2008-3-17
|
pubmed:meshHeading |
pubmed-meshheading:7531965-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:7531965-Adult,
pubmed-meshheading:7531965-Bleomycin,
pubmed-meshheading:7531965-Follow-Up Studies,
pubmed-meshheading:7531965-Humans,
pubmed-meshheading:7531965-Male,
pubmed-meshheading:7531965-Middle Aged,
pubmed-meshheading:7531965-Sarcoma, Kaposi
|
pubmed:year |
1995
|
pubmed:articleTitle |
Intralesional bleomycin for acquired immunodeficiency syndrome-associated cutaneous Kaposi's sarcoma.
|
pubmed:publicationType |
Letter,
Clinical Trial
|